UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000053781
Receipt number R000058860
Scientific Title Intervention study to develop a technique to detect reversible brain fatigue (electronic screen syndrome) by electronic screen using EEG measurement
Date of disclosure of the study information 2024/03/05
Last modified on 2024/03/29 15:08:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Intervention study to develop a technique to detect reversible brain fatigue (electronic screen syndrome) by electronic screen using EEG measurement

Acronym

Intervention study to develop a technique to detect reversible brain fatigue (electronic screen syndrome) by electronic screen using EEG measurement

Scientific Title

Intervention study to develop a technique to detect reversible brain fatigue (electronic screen syndrome) by electronic screen using EEG measurement

Scientific Title:Acronym

Intervention study to develop a technique to detect reversible brain fatigue (electronic screen syndrome) by electronic screen using EEG measurement

Region

Japan


Condition

Condition

healthy volunteers

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Detecting differences in EEG features due to the use of electronic screens using a device

Basic objectives2

Others

Basic objectives -Others

Detection of differences in EEG features depending on the presence or absence of an electronic screen

Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Detection of EEG features with and without electronic screen

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Behavior,custom

Interventions/Control_1

Physically move away from the electronic screen for a certain period of time in daily life

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

1) Adults aged between 18 and 60 at the time of obtaining consent
2) Those who have received sufficient explanation about the purpose and contents of this research, have the ability to consent, voluntarily apply for participation after understanding it well, and can consent to participate in this research in writing.
3) Those who use smartphones frequently (more than 2 hours a day on average for screen time)
4) Those who can come to the measurement venue 2-3 times in total for the measurement

Key exclusion criteria

1) Those who have changed or newly started using health food habitually taken within the past 4 weeks
2) Those who work night shift or day and night shift system
3) Those who are undergoing treatment (hormone replacement therapy, drug therapy, exercise therapy, diet therapy, etc.) at medical institutions for the treatment or prevention of disease, or those who are judged to be in need of treatment.
4) Subjects with a history of diagnosis of serious diseases of glucose metabolism, lipid metabolism, liver function, renal function, heart, circulatory system, respiratory system, endocrine system, immune system nervous system, or mental disease.
5) Those who have a history of alcohol dependence or drug dependence
6) Those who are pregnant, breastfeeding, or wish to become pregnant while participating in the study
7) Participated in other human studies (human studies using foods, drugs, quasi-drugs, medical devices, etc.) within the past 4 weeks, or other studies during the scheduled period of this study plan to participate in a human trial

Target sample size

30


Research contact person

Name of lead principal investigator

1st name TSUYOSHI
Middle name
Last name ISHII

Organization

Rohto Pharmaceutical Co., Ltd.

Division name

Diagnostic Drug & Device Division

Zip code

619-0216

Address

6-5-4 Kunimidai, Kizugawa City, Kyoto, Japan

TEL

0774-71-8774

Email

ishii@rohto.co.jp


Public contact

Name of contact person

1st name EIKO
Middle name
Last name UNO

Organization

Rohto Pharmaceutical Co., Ltd.

Division name

Basic Research and Development Division

Zip code

6190216

Address

6-5-4 Kunimidai, Kizugawa City, Kyoto, Japan

TEL

0774718773

Homepage URL


Email

unoe@rohto.co.jp


Sponsor or person

Institute

Rohto Pharmaceutical Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Rohto Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Rohto Pharmaceutical Co., Ltd. Clinical Research Ethics Review Committee

Address

1-8-1 Tatsumi Nishi, Ikuno , Osaka City

Tel

0774-71-8820

Email

rohtoirb@rohto.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 03 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

33

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 05 Month 09 Day

Date of IRB

2023 Year 06 Month 28 Day

Anticipated trial start date

2023 Year 06 Month 28 Day

Last follow-up date

2023 Year 11 Month 11 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 03 Month 05 Day

Last modified on

2024 Year 03 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058860


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name